ENRUHE
PF-Atlas › How PF-Atlas Works

How PF-Atlas Works

PF-Atlas is a research tracker for pulmonary fibrosis and chronic lymphocytic leukemia. It indexes drugs, trials and papers from public sources, separates clinical fact from computational modeling, and dates every scan. It is built and maintained by an idiopathic pulmonary fibrosis patient. It is not a medical provider and does not give medical advice.

Sources: ClinicalTrials.gov, PubMed, FDA · Last checked: 2026-10-23

Who builds this (Experience)

PF-Atlas is built and maintained by Guy Levin, a person living with idiopathic pulmonary fibrosis. The tool grew from a patient need to see every treatment and trial in one place. The author is accountable and reachable, and the atlas is offered free. Because the maintainer is a patient rather than a clinician, every page separates verified fact from modeling and defers treatment decisions to qualified physicians.

Where the data comes from (Authoritativeness)

Trials come from ClinicalTrials.gov, the public registry of the U.S. National Library of Medicine, keyed by NCT identifier. Papers come from PubMed, keyed by PMID. Drug approvals reference the FDA. Each entity page deep-links its primary source so any claim can be checked at origin.

How the atlas is built (Expertise)

Automated scanning agents query the public registries on a schedule and store new records with their identifiers and scan dates. Every treatment and trial is placed into one of three labeled evidence tiers so a reader can tell an approved drug from a preclinical hypothesis at a glance.

Evidence tiers and honesty (Trust)

PF-Atlas does not invent statistics, licence numbers or expert names. Where a number is shown it comes from a cited source or a clearly labeled computational model. Modeling output is never presented as clinical fact. Corrections are welcome by email.

How PF-Atlas grades evidence
Clinically established. FDA approved or positive Phase III.
Clinical research. In human clinical trials (Phase I to III).
Research model. Computational or preclinical hypothesis, not clinically validated.

What is in the atlas now

35
IPF treatments
2038
IPF trials tracked
419
IPF trials recruiting
14
CLL regimens

Medical disclaimer and editorial policy

PF-Atlas is informational only and is not a substitute for professional medical advice, diagnosis or treatment. It does not recommend treatments or trials. Data can lag the underlying registries. Always consult a qualified pulmonologist or hematologist-oncologist. The author is a patient, not a physician.

Frequently asked questions

Who created PF-Atlas?
PF-Atlas was created and is maintained by Guy Levin, a person living with idiopathic pulmonary fibrosis. It is an independent research atlas, not a medical provider.
Where does PF-Atlas get its data?
Clinical trials come from ClinicalTrials.gov, research papers from PubMed, and drug approval facts reference the FDA. Every entity page links its primary source.
How does PF-Atlas keep data current?
Automated agents scan the public registries on a schedule and store new records with their scan dates. Each page shows when its data was last checked.
Does PF-Atlas give medical advice?
No. PF-Atlas is informational. It does not recommend treatments or trials. Treatment decisions are made with a qualified physician.
How can errors be reported?
Corrections are welcome by email to the maintainer. PF-Atlas does not fabricate statistics, licence numbers or expert names, and modeling is always labeled as such.

Related on PF-Atlas

Not medical advice. PF-Atlas is a research atlas built by a patient, not a healthcare provider. This page is informational and does not recommend any treatment. Always consult a qualified pulmonologist or oncologist before any treatment decision. Editorial policy and how PF-Atlas verifies data.